Goldman Sachs’s AN2 Therapeutics ANTX Stock Holding History
Bought
Maintained
Sold
Other funds holding ANTX
ACA
Goldman Sachs's ANTX Position: Q3 2026 in Review
Goldman Sachs increased its AN2 Therapeutics (ANTX) stake by 622% in Q3 2026, buying an estimated $2.9M and bringing the position to 634,655 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4253.
Goldman Sachs first reported a position in ANTX in Q1 2022 and has held it in 7 quarters since. 84 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.
- Goldman Sachs held 634,655 shares of AN2 Therapeutics worth $3.38M as of Q3 2026.
- Goldman Sachs bought 546,722 AN2 Therapeutics shares in Q3 2026, an estimated $2.9M.
- AN2 Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #4253 holding.
- Goldman Sachs first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 7 quarters since.
- 84 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.